Expanded Functional Genomics Program Sample Clauses

Expanded Functional Genomics Program. (a) During the Initial Development Term, neither Party shall, by itself or via an Affiliate, or by partnering with a Third Party, conduct Development activities on any Respiratory Viral Functional Genomic Screens for Targets associated with Respiratory Viruses or Respiratory Viral Diseases outside of the Collaboration without the other Party’s prior written consent, provided that, (i) with respect to GSK, the foregoing restrictions shall not apply to [***], and (ii) with respect to Vir, the foregoing restrictions shall not apply to [***].
Sample 1
AutoNDA by SimpleDocs
Expanded Functional Genomics Program. During the Research Term, neither Party shall, alone or via an Affiliate or with any third party, work on any Respiratory Viral Functional Genomic Screens [***] for Targets associated with Respiratory Viruses outside of the Collaboration without the other Party’s prior written consent, provided that, with respect to [***]. During the term of the Collaboration, (a) With respect to any Collaboration Target, until the earlier of (i) a Party exercising its opt-out right with respect to such Collaboration Target, or (ii) five (5) years following such Target becoming a Collaboration Target (“Exclusivity Period”), neither Party shall be permitted to, alone or via an Affiliate or partnering with a third party, develop or commercialize any compounds or product directed to such Collaboration Target in [***], provided that, during the Exclusivity Period, if either Party [***] that is then being progressed within the Collaboration, alone or via an Affiliate or partnering with a third party that would otherwise conflict with the restrictions set forth in this paragraph (a), it shall, prior to initiation of such program, propose to include such product [***] to the Collaboration, and then, the following shall apply: (x) if the other Party agrees, then such new product [***] shall be included in the Collaboration, subject to the same terms and conditions hereunder; or (y) if the other Party does not agree, then the proposing Party shall have the right to further progress such program independently (alone or via an Affiliate or partnering with a third party), provided that (1) such Party shall have no right to develop or commercialize any compound or product within such program that is directed to the same Collaboration Target [***] as the Collaboration Target [***] to which any Functional Genomics Product then being progressed in the Collaboration is directed, and (2) the proposing Party shall ensure that no confidential information generated from the Collaboration is used for such product outside the Collaboration. (b) During the Research Term, except as set forth under subclause (c) of the section above entitled “Development of Rejected Targets”, [***]. Notwithstanding the foregoing subclauses (a) and (b), with respect to an Independent Program of a Party directed to a Target that exists as of the date that Screening Data Analysis is provided to the JRDC for such Target, such Party may, in its discretion: (i) continue with such Independent Program, subject to the limit...
Sample 1

Related to Expanded Functional Genomics Program

  • Centralized Functions The Bank of New York Mellon Corporation is a global financial organization that provides services to clients through its affiliates and subsidiaries in multiple jurisdictions (the “BNY Mellon Group”). The BNY Mellon Group may centralize functions including audit, accounting, risk, legal, compliance, sales, administration, product communication, relationship management, storage, compilation and analysis of customer-related data, and other functions (the “Centralized Functions”) in one or more affiliates, subsidiaries and third-party service providers. Solely in connection with the Centralized Functions, (i) the Fund consents to the disclosure of and authorizes the Custodian to disclose information regarding the Fund and the Accounts (“Customer-Related Data”) to the BNY Mellon Group and to its third-party service providers who are subject to confidentiality obligations with respect to such information and (ii) the Custodian may store the names and business contact information of the Fund’s employees and representatives on the systems or in the records of the BNY Mellon Group or its service providers. The BNY Mellon Group may aggregate Customer-Related Data with other data collected and/or calculated by the BNY Mellon Group, and notwithstanding anything in this Agreement to the contrary the BNY Mellon Group will own all such aggregated data, provided that the BNY Mellon Group shall not distribute the aggregated data in a format that identifies Customer-Related Data with the Fund. The Fund confirms that it is authorized to consent to the foregoing and that the disclosure and storage of information in connection with the Centralized Functions does not violate any relevant data protection legislation.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • USE OF THIRD PARTY SYSTEMS-LEVEL SOFTWARE State Street and the Fund acknowledge that in connection with the Data Access Services provided under this Addendum, the Fund will have access, through the Data Access Services, to Fund Data and to functions of State Street’s proprietary systems; provided, however that in no event will the Fund have direct access to any third party systems-level software that retrieves data for, stores data from, or otherwise supports the System.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Development Plan As defined in Section 3.2(a).

  • Development Services Licensee may from time to time wish to augment the RMSS product with additional functionality or utility, or to integrate it with Licensee systems from other sources, and for such purposes may request the provision of development services from RMSS.

  • Hosting Services GSI shall load the Web site onto server(s) that are connected to the Internet and readily accessible via the Web through use of the Domain Names. GSI shall ensure that the Web site is functional and ready to process transactions in a reasonably efficient manner.

  • Marketing Plan The Contractor shall have a Marketing Plan, that has been prior-approved by the SDOH and/or LDSS, that describes the Marketing activities the Contractor will undertake within the local district during the term of this Agreement. The Marketing Plan and all marketing activities must be consistent with the Marketing Guidelines which are set forth in Appendix D, which is hereby made a part of this Agreement as if set forth fully herein. The Marketing Plan shall be kept on file in the offices of the Contractor, LDSS, and the SDOH. The Marketing Plan may be modified by the Contractor subject to prior written approval by the SDOH and/or the LDSS. The LDSS or SDOH must take action on the changes submitted within sixty (60) calendar days of submission or the Contractor may deem the changes approved.

  • Review Systems; Personnel It will maintain business process management and/or other systems necessary to ensure that it can perform each Test and, on execution of this Agreement, will load each Test into these systems. The Asset Representations Reviewer will ensure that these systems allow for each Review Receivable and the related Review Materials to be individually tracked and stored as contemplated by this Agreement. The Asset Representations Reviewer will maintain adequate staff that is properly trained to conduct Reviews as required by this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.